Toshiro Miwa

508 total citations
43 papers, 362 citations indexed

About

Toshiro Miwa is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Toshiro Miwa has authored 43 papers receiving a total of 362 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 7 papers in Epidemiology. Recurrent topics in Toshiro Miwa's work include Lung Cancer Treatments and Mutations (13 papers), Lung Cancer Research Studies (12 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Toshiro Miwa is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), Lung Cancer Research Studies (12 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Toshiro Miwa collaborates with scholars based in Japan and United States. Toshiro Miwa's co-authors include Minehiko Inomata, Ryuji Hayashi, Seisuke Okazawa, Kazuyuki Tobe, Shoko Matsui, Kenta Kambara, Shingo Imanishi, Kensuke Suzuki, Tōru Yamada and Tatsuhiko Kashii and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Biochemical and Biophysical Research Communications.

In The Last Decade

Toshiro Miwa

39 papers receiving 358 citations

Peers

Toshiro Miwa
Minehiko Inomata Japan
Shinichi Yamauchi Japan
Kazuya Tsubouchi Japan
Shinji Ohtake Japan
Tianrui Kuang China
Yiqi Cai China
Yikai Yu China
Qiwei Yao China
Richard Lemal France
F. Calabrese Italy
Minehiko Inomata Japan
Toshiro Miwa
Citations per year, relative to Toshiro Miwa Toshiro Miwa (= 1×) peers Minehiko Inomata

Countries citing papers authored by Toshiro Miwa

Since Specialization
Citations

This map shows the geographic impact of Toshiro Miwa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Toshiro Miwa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Toshiro Miwa more than expected).

Fields of papers citing papers by Toshiro Miwa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Toshiro Miwa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Toshiro Miwa. The network helps show where Toshiro Miwa may publish in the future.

Co-authorship network of co-authors of Toshiro Miwa

This figure shows the co-authorship network connecting the top 25 collaborators of Toshiro Miwa. A scholar is included among the top collaborators of Toshiro Miwa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Toshiro Miwa. Toshiro Miwa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Inomata, Minehiko, Tomomi Ichikawa, Naoki Takata, et al.. (2025). Multicenter Retrospective Analysis of Pulmonary Sarcomatoid Carcinoma Clinically Diagnosed Using Small Biopsy Specimens. Cancer Diagnosis & Prognosis. 5(3). 363–369.
2.
Inomata, Minehiko, Naoki Takata, Seisuke Okazawa, et al.. (2023). Peripheral CD4 memory T cells predict the efficacy of immune checkpoint inhibitor therapy in patients with non-small cell lung cancer. Scientific Reports. 13(1). 10807–10807. 10 indexed citations
3.
4.
Inomata, Minehiko, Seisuke Okazawa, Kenta Kambara, et al.. (2022). Association of Tumor PD-L1 Expression With Time on Treatment Using EGFR-TKIs in Patients With EGFR-Mutant Non-small Cell Lung Cancer. Cancer Diagnosis & Prognosis. 2(3). 324–329. 7 indexed citations
5.
Inomata, Minehiko, Naoki Takata, Seisuke Okazawa, et al.. (2021). Immune Checkpoint Inhibitor for Non-small Cell Lung Cancer With Negative or Low Tumor PD-L1 Expression. Cancer Diagnosis & Prognosis. 1(3). 173–177. 4 indexed citations
6.
Inomata, Minehiko, Naoki Takata, Seisuke Okazawa, et al.. (2021). Case Series of Pleomorphic Carcinoma of the Lung Treated With Immune Checkpoint Inhibitors. In Vivo. 35(3). 1687–1692. 5 indexed citations
7.
Takata, Naoki, Seisuke Okazawa, Kenta Kambara, et al.. (2020). Irinotecan monotherapy as third- or further-line treatment for patients with small cell lung cancer. Tumori Journal. 107(6). 536–541. 2 indexed citations
8.
Inomata, Minehiko, Naoki Takata, Seisuke Okazawa, et al.. (2020). Association of Tumor PD-L1 Expression with the T790M Mutation and Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Receiving EGFR-TKI Therapy. Diagnostics. 10(12). 1006–1006. 13 indexed citations
9.
Inomata, Minehiko, Seisuke Okazawa, Shingo Imanishi, et al.. (2019). Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor. Anticancer Research. 39(12). 6887–6893. 26 indexed citations
10.
Inomata, Minehiko, Seisuke Okazawa, Kenta Kambara, et al.. (2018). Clinical Parameters for Predicting the Survival in Patients with Squamous and Non-squamous-cell NSCLC Receiving PD-1 Inhibitor Therapy. Pathology & Oncology Research. 26(1). 327–333. 18 indexed citations
11.
Inomata, Minehiko, Hiroaki Tanaka, Seisuke Okazawa, et al.. (2017). Clinical Course After Initiation of Nivolumab Therapy in Patients with EGFR-Mutated Non-Small Cell Lung Cancer With or Without Pd-L1 Expression. Oncology and Therapy. 5(2). 181–185. 1 indexed citations
12.
Suzuki, Kensuke, Kenta Kambara, Minehiko Inomata, et al.. (2017). Relationship between Carnitine Pharmacokinetics and Fatigue in Patients Treated with Cisplatin-Containing Chemotherapy. Oncology Research and Treatment. 40(1-2). 42–45. 4 indexed citations
13.
Inomata, Minehiko, Seisuke Okazawa, Kenta Kambara, et al.. (2016). Appetite Loss as an Adverse Effect During Treatment with EGFR-TKIs in Elderly Patients with Non-small Cell Lung Cancer. Anticancer Research. 36(9). 4951–4954. 8 indexed citations
14.
15.
Inomata, Minehiko, Ryuji Hayashi, Seisuke Okazawa, et al.. (2015). Plasma neuron-specific enolase level as a prognostic marker in patients with non-small cell lung cancer receiving gefitinib. Molecular and Clinical Oncology. 3(4). 802–806. 12 indexed citations
16.
Suzuki, Kensuke, Tomomi Ichikawa, Seisuke Okazawa, et al.. (2014). Relationship of the urine cortisol level with the performance status of patients with lung cancer: a retrospective study. Supportive Care in Cancer. 23(7). 2129–2133. 3 indexed citations
17.
Ichikawa, Tomomi, Ryuji Hayashi, Kensuke Suzuki, et al.. (2012). Sirtuin 1 activator SRT1720 suppresses inflammation in an ovalbumin‐induced mouse model of asthma. Respirology. 18(2). 332–339. 71 indexed citations
18.
Gomi, Tomoharu, Fusao Takusagawa, Mikio Nishizawa, et al.. (2008). Cloning, bacterial expression, and unique structure of adenosylhomocysteine hydrolase-like protein 1, or inositol 1,4,5-triphosphate receptor-binding protein from mouse kidney. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics. 1784(11). 1786–1794. 8 indexed citations
19.
Yamada, Tōru, Muneharu Maruyama, Tadashi Fujita, et al.. (2006). Ionizing radiation suppresses FAP‐1 mRNA level in A549 cells via p53 activation. FEBS Letters. 580(18). 4387–4391. 5 indexed citations
20.
Taniguchi, Hirokazu, et al.. (2003). [X-ray-negative endobronchial tuberculosis with persistent irritating cough that resulted in unpredicted mass infection].. PubMed. 41(8). 541–5. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Minehiko Inomata Breakdown of academic impact, for papers by Shinichi Yamauchi Breakdown of academic impact, for papers by Kazuya Tsubouchi Breakdown of academic impact, for papers by Shinji Ohtake Breakdown of academic impact, for papers by Tianrui Kuang Breakdown of academic impact, for papers by Yiqi Cai Breakdown of academic impact, for papers by Yikai Yu Breakdown of academic impact, for papers by Qiwei Yao Breakdown of academic impact, for papers by Richard Lemal Breakdown of academic impact, for papers by F. Calabrese
Rankless by CCL
2026